<DOC>
	<DOCNO>NCT01181167</DOCNO>
	<brief_summary>The objective study assess efficacy safety DU-176b compare enoxaparin sodium prevention venous thromboembolism patient elective total hip arthroplasty .</brief_summary>
	<brief_title>A Study DU-176b , Prevention Venous Thromboembolism Patients After Total Hip Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<criteria>Patients undergo unilateral total hip arthroplasty Subjects risk hemorrhage Subjects thromboembolic risk Subjects weigh less 40 kg Subjects pregnant suspect pregnancy , subject want become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Anticoagulants</keyword>
	<keyword>Venous thromboembolism</keyword>
	<keyword>Thromboembolism</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>enoxaparin sodium</keyword>
	<keyword>Embolism</keyword>
	<keyword>Deep vein thrombosis</keyword>
	<keyword>DU-176b</keyword>
	<keyword>edoxaban</keyword>
	<keyword>factor Xa</keyword>
	<keyword>total hip arthroplasty</keyword>
</DOC>